Kazandjian, Dickran

Genomic Classification and Individualized Prognosis in Multiple Myeloma

Maura, F., Rajanna, A. R., Ziccheddu, B., Poos, A. M., Derkach, A., Maclachlan, K., Durante, M., Diamond, B., Papadimitriou, M., Davies, F., et al. (2024) · Journal of Clinical Oncology

Multiple Myeloma Research and TreatmentsLymphoma Diagnosis and Treatment

Cited by 131

EVIDENCE meta-analysis: evaluating minimal residual disease as an intermediate clinical end point for multiple myeloma

Landgren, O., Prior, T. J., Masterson, T., Heuck, C., Bueno, O. F., Dash, A. B., Einsele, H., Goldschmidt, H., Knop, S., Li, C., et al. (2024) · Blood

Multiple Myeloma Research and TreatmentsStatistical Methods in Clinical Trials

Cited by 131

Whole-genome sequencing reveals progressive versus stable myeloma precursor conditions as two distinct entities

Oben, B., Froyen, G., Maclachlan, K. H., Leongamornlert, D., Abascal, F., Zheng-Lin, B., Yellapantula, V., Derkach, A., Geerdens, E., Diamond, B. T., et al. (2021) · Nature Communications

Multiple Myeloma Research and TreatmentsCancer Genomics and Diagnostics

Cited by 129

Association of Immune Marker Changes With Progression of Monoclonal Gammopathy of Undetermined Significance to Multiple Myeloma

Landgren, O., Hofmann, J. N., McShane, C. M., Santo, L., Hultcrantz, M., Korde, N., Mailankody, S., Kazandjian, D., Murata, K., Thoren, K., et al. (2019) · JAMA Oncology

Multiple Myeloma Research and TreatmentsChronic Lymphocytic Leukemia Research

Cited by 103

Carfilzomib, Lenalidomide, and Dexamethasone Followed by Lenalidomide Maintenance for Prevention of Symptomatic Multiple Myeloma in Patients With High-risk Smoldering Myeloma: A Phase 2 Nonrandomized Controlled Trial

Kazandjian, D., Hill, E., Dew, A., Morrison, C., Roswarski, J., Korde, N., Emanuel, M., Petrosyan, A., Bhutani, M., Calvo, K. R., et al. (2021) · JAMA Oncology

Multiple Myeloma Research and TreatmentsBone health and treatments

Cited by 49

Assessment of Discordance Among Smoldering Multiple Myeloma Risk Models

Hill, E., Dew, A., Morrison, C., Yuan, C., Stetler-Stevenson, M., Landgren, O., & Kazandjian, D. (2021) · JAMA Oncology

Multiple Myeloma Research and TreatmentsChronic Lymphocytic Leukemia Research

Cited by 43

Oncogenic RAS commandeers amino acid sensing machinery to aberrantly activate mTORC1 in multiple myeloma

Yang, Y., Bolomsky, A., Oellerich, T., Chen, P., Ceribelli, M., Häupl, B., Wright, G. W., Phelan, J. D., Huang, D. W., Lord, J. W., et al. (2022) · Nature Communications

PI3K/AKT/mTOR signaling in cancerMultiple Myeloma Research and Treatments

Cited by 29

Genomic profiling to contextualize the results of intervention for smoldering multiple myeloma

Kazandjian, D., Diamond, B., Papadimitriou, M., Hill, E., Sklavenitis-Pistofidis, R., Ziccheddu, B., Blaney, P., Chojnacka, M., Durante, M., Maclachlan, K., et al. (2024) · Clinical Cancer Research

Multiple Myeloma Research and TreatmentsChronic Lymphocytic Leukemia Research

Cited by 16